SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Benz CC, O'Hagan RC, Richter B, et al. HER2/neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene. 1997; 15: 15131525.
  • 2
    Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987; 235: 177182.
  • 3
    Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p 185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14: 737744.
  • 4
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17: 26392648.
  • 5
    Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998; 16: 26592671.
  • 6
    Norton L, Slamon D, Leyland-Jones B, et al. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2 overexpressing (HER2+) metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 127a.
  • 7
    Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelobine in women with HER-2 overexpressing metastatic breast cancer. J Clin Oncol. 2001; 19: 10: 27222730.
  • 8
    Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 18001808.
  • 9
    Crown JP. The platinum agents: a role in breast cancer treatment? Semin Oncol. 2001; 20(1 Suppl 3 ): 2837.
  • 10
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 from metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 11: 783792.
  • 11
    Takakura K, Sano K, Hojo S, et al. Metastatic tumors of the central nervous system. Tokyo: Igaku-Shoin, 1982.
  • 12
    DiStefano A, Yap HY, Hortobagyi GN, et al. The natural history of breast cancer patients with brain metastases. Cancer. 1979; 44: 19131918.
  • 13
    Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastases from breast carcinoma: autopsy study. Cancer. 1983; 52: 23492354.
  • 14
    Lee Y. Breast carcinoma: pattern of metastatic spread at autopsy. J Surg Oncol. 1983; 23: 175180.
  • 15
    Barron KD, Hirano A, Araki S, et al. Experiences with metastatic neoplasms involving the spinal cord. Neurology. 1959; 9: 9195.
  • 16
    Sondak V. Leptomeningeal spread of breast cancer: report of case and review of the literature. Cancer. 1981; 48: 395399.
  • 17
    Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000; 11: 23492351.
  • 18
    Lai RK, Dang C, Thaler H, et al. The incidence of brain metastases in HER2/neu+ stage IV breast cancer patients [abstract]. Proc Am Soc Clin Oncol. 2001;666a.
  • 19
    Miller KD, Weathers T, Haney LG. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors, and impact on overall survival [abstract]. Breast Cancer Res Treat. 2001; 69: 240a.
  • 20
    Wardley AM, Danson S, Clayton AJ, et al. High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center [abstract]. Proc Am Soc Clin Oncol. 2002;241.
  • 21
    Eitzen R, Zach L, Kaufman B, et al. High incidence of brain metastases (BM) in patients on trastuzumab (H) for advanced breast cancer [abstract]. Proc Am Soc Clin Oncol. 2002;31b.
  • 22
    Fokstuen T, Wilking N, Rutqvist LE, et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res and Treat. 2000; 62: 211.
  • 23
    Maki DD, Grossman RI. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol. 2000; 21: 1064.
  • 24
    Esteva FJ, Sahin AA, Cristofanilli M, et al. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol. 2002; 12: 319328.